Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
RYTELOâ„¢ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...